Patents by Inventor Athiwat Hutchaleelaha

Athiwat Hutchaleelaha has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
    Patent number: 11944612
    Abstract: Provided herein are methods for treating sickle cell disease, comprising administering to a subject 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)-methoxy)benzaldehyde (Compound 1), or a polymorph thereof, in certain dosing regimens.
    Type: Grant
    Filed: August 5, 2022
    Date of Patent: April 2, 2024
    Assignee: Global Blood Therapeutics, Inc.
    Inventors: Eleanor L. Ramos, Joshua Eli Lehrer-Graiwer, Athiwat Hutchaleelaha, Naveen Bejugam
  • UNIT DOSE FORMULATION OF ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME
    Publication number: 20230000957
    Abstract: The present invention relates unit dose formulations of antidotes to anticoagulants targeting factor Xa. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.
    Type: Application
    Filed: January 5, 2022
    Publication date: January 5, 2023
    Inventors: Uma Sinha, Genmin Lu, Athiwat Hutchaleelaha, Stanley J. Hollenbach
  • DOSING REGIMENS FOR 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY)BENZALDEHYDE
    Publication number: 20220378770
    Abstract: Provided herein are methods for treating sickle cell disease, comprising administering to a subject 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)-methoxy)benzaldehyde (Compound 1), or a polymorph thereof, in certain dosing regimens.
    Type: Application
    Filed: August 5, 2022
    Publication date: December 1, 2022
    Inventors: Eleanor L. Ramos, Joshua Eli Lehrer-Graiwer, Athiwat Hutchaleelaha, Naveen Bejugam
  • DOSING REGIMENS FOR 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY)BENZALDEHYDE
    Publication number: 20220110928
    Abstract: Provided herein are methods for treating sickle cell disease, comprising administering to a subject 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)-methoxy)benzaldehyde (Compound 1), or a polymorph thereof, in certain dosing regimens.
    Type: Application
    Filed: December 22, 2021
    Publication date: April 14, 2022
    Inventors: Eleanor L. Ramos, Joshua Eli Lehrer-Graiwer, Athiwat Hutchaleelaha, Naveen Bejugam
  • DOSING REGIMENS FOR 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY)BENZALDEHYDE
    Publication number: 20210267956
    Abstract: Provided herein are methods for treating sickle cell disease, comprising administering to a subject 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)-methoxy)benzaldehyde (Compound 1), or a polymorph thereof, in certain dosing regimens.
    Type: Application
    Filed: May 20, 2021
    Publication date: September 2, 2021
    Inventors: Eleanor L. Ramos, Joshua Eli Lehrer-Graiwer, Athiwat Hutchaleelaha, Naveen Bejugam
  • Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
    Patent number: 11020382
    Abstract: Provided herein are methods for treating sickle cell disease, comprising administering to a subject 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)-methoxy)benzaldehyde (Compound 1), or a polymorph thereof, in certain dosing regimens.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: June 1, 2021
    Assignee: Global Blood Therapeutics, Inc.
    Inventors: Eleanor L. Ramos, Joshua Eli Lehrer-Graiwer, Athiwat Hutchaleelaha
  • UNIT DOSE FORMULATION OF ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME
    Publication number: 20210085762
    Abstract: The present invention relates unit dose formulations of antidotes to anticoagulants targeting factor Xa. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.
    Type: Application
    Filed: July 30, 2020
    Publication date: March 25, 2021
    Inventors: Uma Sinha, Genmin Lu, Athiwat Hutchaleelaha, Stanley J. Hollenbach
  • Unit dose formulation of antidotes for factor Xa inhibitors and methods of using the same
    Patent number: 10765726
    Abstract: The present invention relates unit dose formulations of antidotes to anticoagulants targeting factor Xa. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.
    Type: Grant
    Filed: December 6, 2017
    Date of Patent: September 8, 2020
    Assignee: Portola Pharmaceuticals, Inc.
    Inventors: Uma Sinha, Genmin Lu, Athiwat Hutchaleelaha, Stanley J. Hollenbach
  • UNIT DOSE FORMULATION OF ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME
    Publication number: 20180236049
    Abstract: The present invention relates unit dose formulations of antidotes to anticoagulants targeting factor Xa. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.
    Type: Application
    Filed: December 6, 2017
    Publication date: August 23, 2018
    Inventors: Uma Sinha, Genmin Lu, Athiwat Hutchaleelaha, Stanley J. Hollenbach
  • DOSING REGIMENS FOR 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY)BENZALDEHYDE
    Publication number: 20170157101
    Abstract: Provided herein are methods for treating sickle cell disease, comprising administering to a subject 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)-methoxy)benzaldehyde (Compound 1), or a polymorph thereof, in certain dosing regimens.
    Type: Application
    Filed: December 2, 2016
    Publication date: June 8, 2017
    Inventors: Eleanor L. Ramos, Joshua Eli Lehrer-Graiwer, Athiwat Hutchaleelaha
  • UNIT DOSE FORMULATION OF ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME
    Publication number: 20170014492
    Abstract: The present invention relates unit dose formulations of antidotes to anticoagulants targeting factor Xa. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.
    Type: Application
    Filed: July 15, 2016
    Publication date: January 19, 2017
    Inventors: Uma Sinha, Genmin Lu, Athiwat Hutchaleelaha, Stanley J. Hollenbach
  • Unit dose formulation of antidotes for factor Xa inhibitors and methods of using the same
    Patent number: 9056106
    Abstract: The present invention relates unit dose formulations of antidotes to anticoagulants targeting factor Xa. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.
    Type: Grant
    Filed: July 14, 2010
    Date of Patent: June 16, 2015
    Assignee: Portola Pharmaceuticals, Inc.
    Inventors: Uma Sinha, Genmin Lu, Athiwat Hutchaleelaha, Stanley J. Hollenbach
  • UNIT DOSE FORMULATION OF ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME
    Publication number: 20150025011
    Abstract: The present invention relates unit dose formulations of antidotes to anticoagulants targeting factor Xa. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.
    Type: Application
    Filed: June 30, 2014
    Publication date: January 22, 2015
    Inventors: UMA SINHA, GENMIN LU, ATHIWAT HUTCHALEELAHA, STANLEY J. HOLLENBACH
  • INTRAVENOUS AND ORAL DOSING OF A DIRECT-ACTING AND REVERSIBLE P2Y12 INHIBITOR
    Publication number: 20120009172
    Abstract: The invention provides methods and compositions for rapid and reversible inhibition of platelet aggregation in human subjects in need thereof by administering compounds of the formula: alone or in combination with a second agent which can be aspirin or a thrombolytic agent.
    Type: Application
    Filed: September 16, 2011
    Publication date: January 12, 2012
    Applicant: Portola Pharmaceuticals, Inc.
    Inventors: Daniel D. Gretler, Pamela B. Conley, Patrick Andre, Athiwat Hutchaleelaha, David R. Phillips, Anjali Pandey, Robert M. Scarborough, Carroll Anna Crew Scarborough, Wolin Huang
  • UNIT DOSE FORMULATION OF ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME
    Publication number: 20110015128
    Abstract: The present invention relates unit dose formulations of antidotes to anticoagulants targeting factor Xa. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.
    Type: Application
    Filed: July 14, 2010
    Publication date: January 20, 2011
    Inventors: UMA SINHA, GENMIN LU, ATHIWAT HUTCHALEELAHA, STANLEY J. HOLLENBACH
  • INTRAVENOUS AND ORAL DOSING OF A DIRECT-ACTING AND REVERSIBLE P2Y12 INHIBITOR
    Publication number: 20090048216
    Abstract: The invention provides methods and compositions for rapid and reversible inhibition of platelet aggregation in human subjects in need thereof by administering compounds of the formula: alone or in combination with a second agent which can be aspirin or a thrombolytic agent.
    Type: Application
    Filed: May 2, 2008
    Publication date: February 19, 2009
    Applicant: Portola Pharmaceuticals, Inc.
    Inventors: Daniel D. Gretler, Pamela B. Conley, Patrick Andre, Athiwat Hutchaleelaha, David R. Phillips, Anjali Pandey, Robert M. Scarborough, Caroll Scarborough, Wolin Huang